Animal and human data suggest a link between endogenous acid production with elevations in blood pressure and the development of hypertension; increases in endogenous organic acid production can lead to a higher anion gap. We studied the cross-sectional association between the serum anion gap and blood pressure among 1057 nondiabetic patients who were not taking antihypertensive drugs, and who received their care at a multisite, multispecialty group practice in eastern Massachusetts. Using linear regression controlling for age, sex, race, BMI, estimated GFR and presence of impaired fasting glucose, every 1 mEq l À1 higher serum anion gap was associated with a 0.27 mm Hg (P ¼ 0.08) higher systolic, 0.20 mm Hg (P ¼ 0.05) higher diastolic and 0.22 mm Hg (P ¼ 0.04) higher mean arterial pressure; these results suggest that endogenous acid production may raise the risk of hypertension.
Animal and human studies suggest a potential link between acid-base status and elevations in blood pressure (BP). Higher endogenous acid production leads to elevation of the serum anion gap (SAG); however, until recently the association between the SAG and BP had not yet been examined on a population level. We recently reported in the National Health and Nutrition Examination Survey (NHANES) that every 1 mEq l À1 increase in the SAG was associated with a significant 0.48 mm Hg increase in systolic and non-significant 0.16 mm Hg increase in diastolic BP. 1 These findings have not yet been confirmed in a distinct cohort. Here, we report the association between the SAG and BP among 1057 patients followed at a multispecialty group practice.
Using electronic medical records, we identified 10 741 patients who were simultaneously members of both Harvard Pilgrim Health Care and Harvard Vanguard Medical Associates, and continuously enrolled in throughout 1999. Of these, we excluded 7953 who were without a blood measurement of sodium, chloride and bicarbonate on the same date at some point between 1 July 1999 and 31 December 2004. Of the remaining 2788, we excluded 468 without a BMI measurement within 6 months, in either direction, of the blood measurement, 551 with diabetes mellitus before the blood measurement, one non-diabetic who was prescribed metformin and 711 who were prescribed antihypertensive medications during the 6 months before the blood measurement. After these exclusions, 1057 patients remained for analysis. The institutional review boards at Brigham and Women's Hospital and Harvard Pilgrim Health Care approved the conduct of this study.
From electronic medical records, we obtained height and weight, sex, race/ethnicity, and the date of birth. We also assessed baseline impaired glucose tolerance and serum creatinine concentration within 6 months, in either direction, of the blood measurement. We applied the Cockcroft-Gault formula to estimate glomerular filtration rate (cgGFR). 2 The main exposure was the SAG (examined continuously and in quartiles). We computed the SAG using the following equation:
Anion gap ¼ serum sodium ðmEq=lÞ À ½serum chloride ðmEq=lÞ þ serum bicarbonate ðmEq=LÞ
The main outcome measures were systolic and diastolic BP; we also examined mean BP. We chose the BP measurement date closest to, and within 6 months in either direction, of the blood measurement. Using a cross-sectional analysis, we employed crude and multivariable-adjusted linear regression models to examine the relation between the SAG and systolic and diastolic BP, and mean BP. Multivariable models controlled for age, sex, race/ethnicity, BMI, cgGFR and impaired glucose tolerance. Analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC, USA).
The mean SAG in the study population was 10.8 mEq l À1 (s.d. 3.4) and the median was 11 mEq l
À1
(interquartile range, 9-13; 5th-95th percentile, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Tables 1 and 2 .
The SAG was positively associated with BP outcomes in crude and multivariable analyses (Table 1) .
In multivariable models, every 1 mEq l À1 increase in the SAG was associated with a 0.27 (À0.04-0.57) mm Hg increase in systolic BP, a 0.20 (0.0-0.42) mm Hg increase in diastolic BP and a 0.22 (0.01-0.44) mm Hg higher mean BP. Among those patients in the highest quartile of SAG, the systolic BP was 2.9 (0.0-5.8) mm Hg higher than those patients in the lowest quartile after multivariable adjustment. There was a 1.8 (À0.1-3.7) mm Hg higher diastolic BP and a 2.1 (0.1-4.2) mm Hg higher mean BP in the highest compared to lowest quartiles of the anion gap.
In summary, higher SAG was associated with higher BP independent of age, sex, race, BMI, estimated GFR and presence of impaired fasting glucose. Because we excluded individuals with diabetes, as well as those taking antihypertensives (including diuretics) and metformin, it is unlikely concomitant illness and medications confounded the observed association. Furthermore, the median and mean values for the SAG in our population were within the normal range; therefore, it is unlikely that ours is a highly biased population. Our observations from this clinical cohort support and confirm our findings from the randomly selected NHANES research cohort. 1 While the explanation for the relation between the SAG and BP is unknown, it is possible that higher SAGs in our population reflect higher levels of unmeasured organic anions that are conjugate bases of organic acids. Thus, increased endogenous acid production could explain higher SAGs. Both animal and human data suggest an association between increased endogenous acid production, salt-sensitivity and hypertension. For example, spontaneously hypertensive rats have lower serum bicarbonate concentrations and lower blood pH compared to control normotensive rats; these acid-base abnormalities precede the development of hypertension. 3 Dahl salt-sensitive rats have lower intracellular pH and higher renal acid excretion compared to control salt-resistant rats on similar diets, implicating higher endogenous acid production in salt-sensitive animals. 4 In 40 normotensive humans on a fixed low-salt diet, a sodium chloride load simultaneously increased BP and decreased both arterial pH and serum bicarbonate. 5 These same investigators also demonstrated that urinary bicarbonate excretion among salt-sensitive compared to salt-resistant individuals was 32 and 46% lower in response to an oral citrate load on fixed high-salt and low-salt diets, respectively. 6 The authors hypothesized that these findings could be explained as a compensatory mechanism to increased endogenous acid production among saltsensitive individuals. 6 Among more than 3000 participants of three large cohort studies (Nurses' Health Study 1, NHS1; Nurses' Health Study 2, NHS2; Health Professionals' Follow-up Study, HPFS), the adjusted odds ratios for prevalent hypertension among participants in Hypocitraturia (o320 mg day À1 ) was associated with significant 2.4-2.8-fold higher odds of prevalent hypertension in these cohorts. Urinary citrate excretion is regulated by systemic acid-base status, such that systemic acidosis and thus decreases in the intracellular pH of renal proximal tubular cells leads to decreases in urinary citrate. 8 There are also ample data to suggest that saltsensitivity may not be solely due to the sodium ion. In several metabolic studies conducted with participants on controlled diets, ingestion of sodium chloride led to increases in BP whereas ingestion of alkali salts such as sodium bicarbonate and sodium citrate did not. 5, [9] [10] [11] In one study of individuals on a moderate sodium diet (60 mmol day À1 ), 7 days consuming a sodium bicarbonate drink actually lowered BP by 5 mm Hg. 10 In another study that measured plasma volume changes among individuals on a lowsalt diet (10 mmol day À1 ), sodium chloride administration increased plasma volume in conjunction with BP whereas sodium citrate administration had no effect on either blood pressure or plasma volume. 9 It is possible that these findings stem from a protective effect of alkali on BP in salt-sensitive individuals, although this is purely hypothetical.
Our study has clear limitations. First, because this population comprised patients followed at a multispecialty group practice, electrolyte measurements, which enabled patients to be included in our analyses, were at the discretion of treating clinicians and were more likely to be performed in sicker individuals. However, we excluded patients with diabetes, and excluded patients on antihypertensive medications; furthermore, these electrolyte measurements were performed in the outpatient setting, and the median and mean SAG values were normal. Thus, while our study population may have had more comorbidity than the general adult population, we feel this bias does not markedly detract from our findings. Moreover, we observed a similar relation in the NHANES cohort, which is not subject to this type of potential bias.
1 Second, we lacked serum albumin measurements, and thus could not correct anion gaps upward in the setting lower serum albumin. However, albumin concentration and BP are positively related. 12 Therefore, low albumin concentrations simultaneously increase the SAG and are associated with lower BP, so correction for low albumin concentrations would likely have strengthened the observed association between the SAG and BP. Third, our study was cross-sectional so we cannot conclude that a higher SAG is indeed a risk factor for elevations in BP; rather, it is possible that higher BP is a risk factor for an elevated SAG via an unclear mechanism.
In conclusion, a higher SAG is associated with higher BP. These data lend support to the hypothesis that increased endogenous acid production may play a role in hypertension. Prospective studies are needed to determine if the SAG is indeed a risk factor for the development of hypertension. If this association is confirmed by prospective studies, then alkali therapy could potentially be employed in clinical trials to lower BP and prevent hypertension.
